14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NMR vs DCM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over DCM (DCM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin), whereas DCM carries 48.8/100 (HOLD) at $2.82 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While DCM currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. NMR 35.0/100 SELL), NMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (25.1% vs. N/A operating margin) and revenue trajectory (+17.9% vs. N/A YoY).
Technical & Structure Timing Caution: NMR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4); meanwhile DCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs DCM. Trailing 12-month operating profitability (NMR 25.1% vs DCM N/A) and valuation multiples (NMR 11.4x vs DCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NMR vs DCM Key Questions & Quantitative Answers
As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over DCM (DCM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin), whereas DCM carries 48.8/100 (HOLD) at $2.82 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While DCM currently prints a higher short-term Unified Composite Score (48.8/100 HOLD vs. NMR 35.0/100 SELL), NMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (25.1% vs. N/A operating margin) and revenue trajectory (+17.9% vs. N/A YoY). Technical & Structure Timing Caution: NMR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4); meanwhile DCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMR leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with DCM at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus N/A for DCM. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DCM.
NMR screens cheaper on headline valuation multiples. NMR trades at 11.4x Forward P/E, 10.4x Trailing P/E, 0.81x PEG, and 1.8x EV/Revenue (unreported cash flow margin), whereas DCM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus DCM (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 34% Vol realized risk). By comparison, DCM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.